MeiraGTx price target raised to $14 from $12 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on MeiraGTx (MGTX) to $14 from $12 and keeps a Buy rating on the shares, citing a ...
BioPharma Dive1d
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...
Fierce Biotech1d
Hologen AI commits $430M to MeiraGTx Parkinson’s gene therapy
With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...
Bank of America Securities Sticks to Their Buy Rating for Meiragtx Holdings (MGTX)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Meiragtx Holdings (MGTX – Research Report) today and set a price ...
This Founder’s Gene Therapy Company Helped Blind Kids See Again
Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars
MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in ...
MeiraGTx (MGTX) Expected to Announce Earnings on Thursday
MeiraGTx (NASDAQ:MGTX – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, ...